CIK 0001766140 · <br>Emerging growth company
Unicycive Therapeutics, Inc.
Sign in to watch- Ticker
- UNCY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813638692
- Phone
- 650-384-0642
- Business address
- 1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW, CA, 94040
- Former names
- Unicycive Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-25 | Aggarwal Gaurav Director | Conversion | +652,900 | 1,789,915 | ||
| 2025-08-25 | Aggarwal Gaurav Director | Returned to the company · Series A-2 Prime Preferred Stock | −3,199.21 | $1,000.00 | $3.2M | 0 |
| 2025-07-28 | Aggarwal Gaurav Director | Grant or award · Stock Options | +21,200 | 39,200 | ||
| 2025-07-28 | Laumas Sandeep Director | Grant or award · Stock Options | +21,200 | 41,286 | ||
| 2025-07-28 | Kenkare-Mitra Sara Director | Grant or award · Stock Options | +21,200 | 39,200 | ||
| 2025-07-28 | Gupta Shalabh K. CEO | Grant or award · Stock Options | +325,000 | 968,951 | ||
| 2025-07-28 | Townsend John Chief Financial Officer | Grant or award · Stock Options | +10,000 | 101,557 | ||
| 2025-07-28 | Gupta Pramod EVP, Pharmaceuticals and BD | Grant or award · Stock Options | +90,000 | 301,986 | ||
| 2025-07-28 | Jermasek Douglas EVP of Corporate Strategy | Grant or award · Stock Options | +10,000 | 215,500 | ||
| 2025-02-18 | Aggarwal Gaurav Director | Conversion | +1,400,000 | 11,370,152 | ||
| 2025-02-18 | Aggarwal Gaurav Director | Returned to the company · Series A-2 Prime Preferred Stock | −686 | $1,000.00 | $686K | 3,119.21 |
| 2024-10-09 | Aggarwal Gaurav Director | Conversion | +5,500,000 | 9,970,152 | ||
| 2024-10-09 | Aggarwal Gaurav Director | Returned to the company · Series A-2 Prime Preferred Stock | −2,695 | $1,000.00 | $2.7M | 3,885.21 |
| 2024-08-12 | Gupta Pramod EVP, Pharmaceuticals and BD | Grant or award · Stock Options | +81,750 | 2,119,862 | ||
| 2024-08-12 | Townsend John Chief Financial Officer | Grant or award · Stock Options | +40,256 | 915,565 | ||
| 2024-08-12 | Jermasek Douglas EVP of Corporate Strategy | Grant or award · Stock Options | +81,750 | 2,055,000 | ||
| 2024-08-12 | Gupta Shalabh K. CEO | Grant or award · Stock Options | +232,868 | 6,439,505 | ||
| 2024-04-15 | Townsend John Chief Financial Officer | Grant or award · Stock Options | +228,119 | 875,309 | ||
| 2024-04-15 | Jermasek Douglas EVP of Corporate Strategy | Grant or award · Stock Options | +463,250 | 1,973,250 | ||
| 2024-04-15 | Gupta Pramod EVP, Pharmaceuticals and BD | Grant or award · Stock Options | +463,250 | 2,038,112 |
Page 2 of 5 · 84 trades